Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  Koffiekamer  /  Aptevo therapeutics

Ontvang nu dagelijks onze kooptips!

word abonnee

Koffiekamer« Terug naar discussie overzicht

Aptevo therapeutics

78 Posts
Pagina: «« 1 2 3 4 »» | Laatste | Omlaag ↓
  2. forum rang 5 MisterBlues 4 november 2020 14:12
    quote:

    Wolfgang schreef op 3 november 2020 18:21:

    Als je ze nog goedkoop wil denk ik dat je snel gaat moeten zijn. www.biospace.com/article/releases/apt...
    Succes binnen fase 1, en dat is heel wat na de enorme tegenslag. Amerikanen overdrijven altijd en ooit was het aandeel enorm in de belangstelling. Vandaar die explosie van ca 80%

    Fase 1: het is nog een lange weg te gaan...je hebt het over 1 patiënt.
  5. forum rang 5 MisterBlues 4 november 2020 22:14
    quote:

    Wolfgang schreef op 4 november 2020 20:57:

    Ja 1 patiënt die kankervrij het ziekenhuis heeft verlaten.
    Zoiets zie je toch niet snel.
    Ze moeten idd bevestigen dat het op grotere groepen dezelfde resultaten heeft.

    Maar je kan toch wel zeggen dat het bedrijf meer waard moet zijn dan de huidige 45mil. Maak ermaar 300 van

    1. Kan ook toeval zijn. Zegt nu idd nog vrij weinig. Statisch significant, double blind en gerandomiseerd onderzoek is different koek.

    2. Het gaat er vooral om of dat biotech platform iets voorstelt.

    Nogmaals het bedrijf was eerst de hemel beloofd. Daarom kan ik me deze opleving wel voorstellen na een klein succesje - maar van fase 1 naar 2 is de stap met het grootste risico in biotech. Juich niet te vroeg.

    Wat de waarde precies is van biotech is verder niet zo relevant. Het gaat om succesvolle onderzoeken, geld in de lade en cashburn.

  9. forum rang 5 MisterBlues 6 november 2020 08:24
    quote:

    Lego schreef op 5 november 2020 19:06:

    Momenteel weeral 40% in de plus. Dat is een stijging van 235% op een paar dagen al... Het geloof is groot in dit aandeel.
    Dat is typisch voor deze fase in biotech. Met 1 patiënt heb je doorgaans weinig complicaties. Het risico wordt steeds groter, van fase 1 naar 2 met tientallen patiënten en fase 3 met honderdtallen of meer.

    Verder heeft het platform een belofte van een 'moleculengenerator'...

    Het aandeel stond op de top ooit op 80. Er zit best nog wat upside maar het op een gegeven moment daalt de werkelijkheid weer in.
  10. Wolfgang 6 november 2020 15:53
    quote:

    Lego schreef op 5 november 2020 19:06:

    Momenteel weeral 40% in de plus. Dat is een stijging van 235% op een paar dagen al... Het geloof is groot in dit aandeel.
    Het bedrijf heeft maar 3 Mil aan openstaande aandelen na de reverse split.
    Normaal zitten we nu op 1.40€ met een markt cap van 68 Mil.
    Vind ik niet overdreven hoog of snel.

    Het kan dus snel omhoog en ook naar omlaag gaan.

    Bij nog meer goed nieuws kan het echt gaan vliegen.
    Maar het is en blijft gericht gokken.
  13. Wolfgang 7 november 2020 13:37
    quote:

    DeZwarteRidder schreef op 7 november 2020 11:55:

    De enige vraag is: wanneer dondert de koers weer in elkaar...???
    Thx voor jullie inzicht en info. Whatever

    form 4 disclosed today shows that kevin now owns about 55% of the company's outstanding shares - most of them were acquired during the last three days after the remission news.
    whether he wants the whole company or a big chunk of it is unknown, 90% of chance is that he is after the whole company but the company can refuse and turn the whole thing ugly, I think
    both should be working hard during the weekend and Monday will be very interesting, we might see 100-200 dollar per share in the open....
  17. forum rang 5 MisterBlues 8 november 2020 11:58
    quote:

    Wolfgang schreef op 7 november 2020 13:37:

    [...]

    Thx voor jullie inzicht en info. Whatever

    form 4 disclosed today shows that kevin now owns about 55% of the company's outstanding shares - most of them were acquired during the last three days after the remission news.
    whether he wants the whole company or a big chunk of it is unknown, 90% of chance is that he is after the whole company but the company can refuse and turn the whole thing ugly, I think
    both should be working hard during the weekend and Monday will be very interesting, we might see 100-200 dollar per share in the open....
    Het wordt zeker interessant. Waarschijnlijk wist die Kevin van de koopverplichting van de shorters. Gaan we eerst eerst hard omhoog en vervolgens hard omlaag omdat Kevin er weer ten dele uitstapt en/of andere korte termijn handelaren die dat (ook) doen?
  18. forum rang 5 MisterBlues 8 november 2020 12:02
    Aptevo sells off after clarifying complete response in early-stage study on lead drug
    Nov. 5, 2020 8:57 AM ET|About: Aptevo Therapeutics Inc. (APVO)|By: Douglas W. House, SA News Editor

    Nano cap Aptevo Therapeutics (NASDAQ:APVO) retraces 12% premarket on increased volume on the heels of its 170% two-day rally after announcing a complete remission (CR) in a Phase 1 clinical trial evaluating lead candidate APVO436 in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

    The CR was observed in a participant in cohort 6 after five cycles of treatment, not two which was originally reported.

    CEO Marvin White says, "We are greatly encouraged by the complete remission in the patient in cohort 6. We are now in a critical phase of the study, as pharmacokinetic modelling suggests that dosing in cohorts 5 through 8 is in a therapeutic range which could result in potential clinical activity of the drug. We look forward to continuing the dose escalation and monitoring potential clinical responses as we advance through the upcoming dose cohorts."

    APVO436 is an anti-CD123 x anti-CD3 bispecific antibody (binds to two unique antigen targets simultaneously) based on the company's ADAPTIR platform.
  19. Wolfgang 8 november 2020 14:46
    Ik ga ze toch verkopen maandag.
    Die kevin tang gaat over lijken om maar geld te verdienen en geeft volgens mij niet veel om het bedrijf en om de andere aandeelhouders.

    Een oud artikel over hem

    WSB Meet Kevin Tang of Heron Therapeutics. One of us

    Kevin Tang is one lucky dude.

    Tang, the activist manager of the health care hedge fund Tang Capital Partners, has an unusual strategy: liquidate underperforming biotech companies. Here's how it works...

    The credit crisis – and the ensuing risk-aversion – has driven investors miles away from small biotechs. When sellers far outnumber buyers, a strange phenomenon happens. These stocks get pushed below the amount of cash the companies have in the bank (a condition called "negative enterprise value").

    In theory, if you buy the stock at these depressed prices, you can generate instant, guaranteed returns by shutting the company down and returning the existing cash to shareholders. For Kevin Tang, it's not theory. He puts it into practice.

    Recently, Maryland-based Vanda Pharmaceuticals became Tang's prime target. The company had developed the drug Fanapt for schizophrenia. But the FDA rejected it last July, demanding more clinical trials. Shares fell from a high of $29 in 2007 to less than $1 after the rejection. Still, Vanda persisted. It believed it could convince the FDA to approve Fanapt without any new trials.

    I thought the Vanda management team was either crazy or brilliant. I figured their chances of success were less than 1 in 1,000. Apparently, so did Kevin Tang.

    Tang knew Vanda's stock was worth much more than $1. In fact, the company was sitting on about $1.70 per share in cash after accounting for all its liabilities. So he moved in and scooped up almost 4 million shares (15% of the company) at less than $1. Then, he demanded management close shop and return the cash to shareholders. If the strategy succeeded, he would be sitting on a 70% return in less than a year. But, boy, he couldn't have been more wrong...

    On May 6, the FDA did the unthinkable. It approved Fanapt for schizophrenia, dropping its request for new trials. The agency's miraculous change of heart was shocking and unprecedented. The next morning, Vanda's stock jumped 920% at the open. Yes, you are reading it right – a "10-bagger" in a single day.

    Tang's original stake of roughly $4 million is worth more than $50 million today. (And yes, he immediately withdrew his proposal to liquidate the company.)

  20. forum rang 5 MisterBlues 9 november 2020 09:55
    finance.yahoo.com/news/aptevo-therape...

    Aptevo Therapeutics Adopts Limited Duration Stockholder Rights Plan

    Mon, November 9, 2020, 5:15 AM GMT+1

    SEATTLE, WA / ACCESSWIRE / November 8, 2020 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan and declared a dividend distribution of one right for each outstanding share of common stock. The record date for such dividend distribution is November 23, 2020. The rights plan expires, without any further action being required to be taken by Aptevo's Board of Directors, on November 8, 2021.

    The adoption of the rights plan is intended to protect Aptevo and its stockholders from the actions of third parties that Aptevo's Board of Directors determines are not in the best interests of Aptevo and its stockholders, and to enable all stockholders to realize the full potential value of their investment in Aptevo. The rights plan provides the Board of Directors with time to make informed decisions that are in the best long-term interests of Aptevo and its stockholders and does not prevent Aptevo's Board of Directors from considering any offer to acquire Aptevo that it considers to be in the best interest of Aptevo's stockholders.

    The rights plan is similar to stockholder rights plans adopted by other publicly-traded companies. Under the rights plan, the rights generally would become exercisable only if a person or group acquires beneficial ownership of 10% or more of Aptevo's common stock in a transaction or series of transactions not approved by Aptevo's Board of Directors. In that situation, each holder of a right (other than the acquiring person or group, whose rights will become void and will not be exercisable) will have the right to purchase, upon payment of the exercise price and in accordance with the terms of the rights plan, a number of shares of Aptevo's common stock having a market value of twice such price. In addition, if Aptevo is acquired in a merger or other business combination after an acquiring person acquires 10% or more of Aptevo's common stock, each holder of the right would thereafter have the right to purchase, upon payment of the exercise price and in accordance with the terms of the rights plan, a number of shares of common stock of the acquiring person having a market value of twice such price. The acquiring person or group would not be entitled to exercise these rights. In the rights plan, the definition of "beneficial ownership" includes derivative securities.
78 Posts
Pagina: «« 1 2 3 4 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 865,83 +0,06%
EUR/USD 1,0673 +0,02%
FTSE 100 7.866,99 +0,24%
Germany40^ 17.755,40 -0,08%
Gold spot 2.378,15 +0,73%
NY-Nasdaq Composite 15.683,37 -1,15%

Stijgers

VIVORY...
+15,54%
Air Fr...
+3,63%
Alfen ...
+2,99%
B&S Gr...
+1,98%
AZERION
+1,56%

Dalers

Pharming
-8,28%
PostNL
-5,92%
ASMI
-2,62%
Accsys
-2,39%
Avantium
-1,94%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!